Lecanemab (LEQEMBI)

About Eisai

Eisai is a fully integrated, patient-centric biopharmaceutical company with a mission to give first thought to patients and their families. Its strategic focus on neurology and oncology has yielded landmark achievements, most notably the commercialization of the first disease-modifying Alzheimer's therapy, LEQEMBI, in partnership with Biogen. The company complements its commercial success with a deep, long-standing commitment to sustainability and global health, distributing billions of treatments for neglected tropical diseases. Financially robust and strategically disciplined, Eisai is leveraging its neuroscience leadership to expand its oncology portfolio and solidify its long-term growth trajectory.

About Biogen

Founded in 1978, Biogen has established itself as a cornerstone of the biotechnology industry, renowned for pioneering multiple sclerosis treatments and launching the first approved therapy for Alzheimer's disease. The company's strategy is anchored in a focused R&D engine that reinvests approximately $2 billion annually into neurology, immunology, and rare disease pipelines, balancing bold scientific risk with disciplined capital allocation. Its mission is to translate cutting-edge science into transformative medicines, creating value for patients, shareholders, and communities.

About bioarctic-ab

BioArctic AB is a research-intensive Swedish biopharma focused on translating novel insights into protein aggregation pathology into transformative treatments for neurodegenerative diseases. Its strategic triumph is the Eisai-partnered anti-amyloid beta protofibril antibody lecanemab (Leqembi®), which achieved FDA approval in 2023, validating the company's core scientific thesis. The company's strategy balances revenue from this landmark partnership with advancing a wholly-owned pipeline targeting alpha-synuclein in Parkinson's disease, leveraging its proprietary BrainTransporter® platform to enhance drug delivery to the brain. With a market cap nearing $28 billion, BioArctic stands as a premier European biotech success story.

Therapeutic Areas

Other Alzheimer's Disease Drugs